



12TH DIGITAL PATHOLOGY & AI CONGRESS: EUROPE

UTILIZING DIGITAL PATHOLOGY & AI TO ADVANCE PATHOLOGY PRACTICE,
ENABLE ENHANCED PATIENT CARE AND FURTHER DRUG DISCOVERY

LONDON HILTON METROPOLE - LONDON, UK
10-11 December 2025



#DigiPathLondon

www.global-engage.com



Global Engage is pleased to announce the **12th Digital Pathology & AI Congress**, which is confirmed to take place on 10-11 December 2025 in London, UK at the London Hilton Metropole.

This internationally recognised meeting brings together 600+ attendees and 60+ exhibitors to discuss and collaborate on the latest advances, developments and case studies in the Digital Pathology & AI field. As digital workflows become the norm, the focus now turns to refining digital workflows and how the future of Digital Pathology & AI may lead us to precision medicine approaches for disease treatment.

Conference Session Schedule

	Track 1	Track 2	Track 3
Day 1	Imaging AI & Digital Image Analysis	Challenges with Implementation, Workflow, and Standardisation	Digital Pathology & AI in Pharma
Day 2	Computational Pathology & AI	Challenges with Implementation, Workflow, and Standardisation	Digital Pathology & AI in Pharma

- 60 strong senior level speaker faculty
- Expert-led roundtables and interactive panel sessions
- Exhibition hall for 60+ technology providers
- Unique academic and pharma/biotech joint focus
- Poster presentations/ competition to promote scientific development
- Over 7 hours of networking time

Reasons to attend

Are you:-

- Looking to optimise your digital workflow and overcome potential challenges with LIMS?
- Keen to know more about AI regulation and ethics in Digital Pathology?
- Interested in learning about Digital Pathology and AI integration in clinical trials?
- An experienced user looking to uncover the latest advances, developments and case studies in the field?

This congress is not to be missed and is a must attend event for anyone wanting to invest or utilize digital pathology to its full potential.



Medical staff and clinical scientists in career grade posts who are enrolled with one of the Royal Colleges for CPD purposes and attend the meeting will be entitled to receive 11 CPD credits.



Dear Colleagues,

The digital transformation of pathology is no longer a future vision—it is happening now. It requires more than technology adoption; it demands leadership, strategic investment, and collaboration across disciplines.

I'm honored to return as a keynote speaker at the 12th Digital Pathology & AI Congress: Europe, taking place this December in London. My talk, titled:

"Computational Pathology as a Strategic Asset: Leadership Lessons from the Frontlines," will cover:

- Why I built a dedicated Computational Pathology Division—and why you should too.
- How every Department of Pathology can benefit from an AI Center.
- How our Office of Collaborative Pathology serves as a new model for innovation.

I've attended these congresses for years—both in the USA and London—and I'm thrilled to be back after a brief hiatus. These meetings have grown tremendously, offering outstanding content and exceptional networking opportunities. The organizers always take great care of participants (the catering is truly excellent!), and I'm especially pleased that the venue is now in central London, making it easier to enjoy this incredible city.

This congress remains an influential gathering in our field. I look forward to reconnecting, sharing insights, and learning from one another as we shape the future of pathology together.

Warm regards,

Liron Pantanowitz, MD

Professor and Chair, Department of Pathology
University of Pittsburgh

Platinum Sponsors



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Other Exhibitors & Sponsors



Event Supporters



Media Partners




DARREN TREANOR

Consultant Pathologist, Clinical Professor of Pathology, Adjunct Professor of Digital Pathology, Director, Leeds Teaching Hospitals NHS Trust, University of Leeds, Linköping University, National Pathology Imaging Co-operative


ALEKSANDRA ZURAW

Founder, Digital Pathology Place, Veterinary Pathologist, Charles River Laboratories


JAN VON DER THUSEN

Consultant Histopathologist, Erasmus MC


MICHAEL VALANTE

Global Business Lead, Healthcare and Life Science UDS, CTO, Digital Pathology, Dell Technologies


MONIKA LAMBA SAINI

Global Translational Pathology Leader, ADC Therapeutics, Education Committee, Digital Pathology Association


MANUEL SALTO-TELLEZ

Professor of Integrated Pathology & Director of the Integrated Pathology Unit, Institute of Cancer Research & Royal Marsden Hospital, London, Professor of Molecular Pathology & Director of the Precision Medicine Centre, Queen's University Belfast


DAVID SNEED

Professor & Consultant Pathologist, Director, University Hospitals Coventry & Warwickshire NHS Trust, PathLAKE, Warwick Medical School Coventry


ELENA MIRANDA

Director, Non-Clinical Histology, GSK


ALEXANDER WRIGHT

Head of Research Infrastructure, National Pathology Imaging Co-operative


ELIZABETH NEYENS

Principal Consultant, Toxicologic Pathologist, ElizabethToxPath Consulting Inc


LISE BERTRAND

Scientific Director, Digital Pathology, Charles River Laboratories


FRIEDRICH PREUSSER

Principal Image Data Scientist, Vizgen


DONAL O'SHEA

PhD, Chief Executive Officer, Deciphex/Diagnexia


MARION GEERLIGS

Digital Pathology Category Leader, Philips


BOBBI PRITT

Chair of Clinical Microbiology, Mayo Clinic, USA


CELINE DEGALLIER

Scientific Collaborator, Anatomic Pathology Department, University Hospital Brussels


ERIO BARALE-THOMAS

Senior Principal Scientist, Pathobiology, Johnson & Johnson


MANU SEBASTIAN

Professor, University of Texas MD Anderson Cancer Centre


IAN MASON

Programme Head, Digital Deployment & Business Services, National Pathology Imaging Co-operative (NPIC)


PETER GROSS

Principal Scientist, Boehringer Ingelheim


SHOKO VOS

Consultant Pathologist, Radboud University Medical Center


JOJANNEKE DROGT

Medical Ethicist and Postdoctoral Researcher, University Medical Center Utrecht


DEBRA PADGETT

Clinical Pathology Lead & Lead Healthcare Scientist, Northumbria Healthcare NHS Foundation Trust, NENC Pathology Network Operational Lead


CHRISTOS MATSOUKAS

Associate Director, Artificial Intelligence, AstraZeneca, Sweden


CHAITH KONDRAGUNTA

CEO, AIRA Matrix


JAMES THACKERARY

Chief Executive Officer, Lumea


LORCAN SHERRY

Chief Scientific Officer, OracleBio


CHRISTOPHER MILLS

Senior Scientist, Concept Life Sciences


SENIOR REPRESENTATIVE

Jusha


MANASI AICHMUELLER-RATNAPARKHE

Co-Founder & CEO, PAICON GmbH


AYESHA AZAM

Consultant Histopathologist and Recipient of NIHR Senior Clinical Practitioner Research Award, University Hospitals Coventry & Warwickshire NHS Trust


JON GRIFFIN

Senior Clinical Lecturer and Honorary Consultant Histopathologist, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust


MAC (ROBERT) MACAULAY

Pathology LIMS Manager, Deputy Head of Pathology IT, DHP SME, Pathology IT and Transformation, University Hospitals Sussex NHS Foundation Trust


CHRISTOPHER WALSH

Research Associate, University of Glasgow, CEO, TileBio Ltd


FRANCESCO CIOMPI

Associate Professor and Research Group Leader of AI for Precision Medicine, Radboud University Medical Center


YURI TOLKACH

Senior Attending Physician, Research Group Lead, Institute of Pathology, University Hospital Cologne


DAVID DE MENA

Global Digital Pathology IT Content Manager, Leica


NIRAV GANDHI

Consultant Cellular Pathologist, University Hospitals of Derby and Burton NHS Foundation Trust


ARTHUR LEWIS

Director of Pathology, Clinical Pharmacology and Safety Sciences



(CPSS), AstraZeneca

LIRON PANTANOWITZ

Professor and Chair of Pathology, University of Pittsburgh, USA


JO MARTIN

Professor of Pathology, Deputy Vice Principal Health, Queen Mary University of London


HAKIMA IBAROUDENE

Manager R&D, Southwest Research Institute


DIANA MONTEZUMA

Pathologist and Head of the R&D Unit, IMP Diagnostics


ABHI GHOLAP

Founder, OptraSCAN, Inc.


CATHERINE GUETTIER

Emeritus Professor of Pathology Université Paris Saclay - Assistance Publique Hôpitaux de Paris, Consultant for Aiforia Technologies Oyj


CHRIS POLLEY

Digital Pathology Business Development Specialist EMEA, Evident Scientific


DR NICHOLAS SPENCER

Global Chief Clinical Information Officer, AGFA HealthCare


PAUL MESANGE

Global Director, Histology, Labcorp


NORMAN ZERBE

Head of Digital Pathology Research, Charité - Universitätsmedizin Berlin


BRANKO PERUNOVIC

Chief Medical Officer, Black Country Pathology Service, (BCPS), Royal Wolverhampton NHS Trust


MIEKE VERSLEGERS

Principal Scientist Pathobiology, Preclinical Sciences and Translational Safety, Johnson & Johnson Innovative Medicine


LUISA BELL

Neuropathology Scientist, Roche


BARKHA GUPTA

Senior Medical Pathologist, Sanofi


AMAL ASAR

Consultant Histopathologist, Northern Care Alliance


KATHERINE GLAZEBROOK

Senior ICT Programme Manager, Black Country Pathology Service


DAVID CLARK

Consultant Pathologist, Nottingham University Hospitals NHS Foundation Trust


RADHA KRISHNAN

Head of Clinical Pathology, MSD


USMAN ARIF

Programme Head - Digital, Data & IT Services, National Pathology Imaging Co-operative (NPIC)


ADAM LEVINE

Academic Consultant Pathologist, UCL and UCLH


SHAMILA JABBAR

Lead Biomedical Scientist, National Pathology Imaging Co-operative (NPIC)

CONFIRMED & RESERVED SPEAKERS



RYAN POWERS
VP, Global Life Sciences,
Aira Matrix



ALYN CRATCHLEY
NPIC Clinical Lead / Consultant
Pathologist, National Pathology Imaging
Co-operative (NPIC)



SIDNEY OCANAGIL-TUNSTALL
Marketing Director, Pathology News



PETER CAIE
Sr. Principal Scientist, AI Diagnostics,
Indica Labs



WIM WAELPUT
Senior Pathologist, University Hospital
Brussels



ORLY ARDON
Director Digital Pathology Operations
and Assistant Attending, Memorial Sloan
Kettering Cancer Center






12TH DIGITAL PATHOLOGY & AI CONGRESS: EUROPE

LONDON

10-11 December 2025

KEY

- Allocated Exhibition Space
- Available Exhibition Space
- Lunch / Refreshment Station
- To / From Conference Rooms



#1	The Pathologist	#20	A.Menarini	#38	Spotlight Pathology	#56	Infinit Europe GMBH
#2	Merge by Merative	#21	Proscia	#39	HistologiX	#57	Diagnexia
#3	Sysmex	#22	Lumea	#40	Evident Scientific	#58	Diagnexia Analytix
#5	Leica Biosystems	#23	Philips	#41	EIZO	#59	IBEX
#7	Indica Labs	#24	Siemens Healthcare	#42	Roche	#60	ELEA Health
#8	OptraScan	#25	OracleBio	#43	Aurora mScope Inc.	#61	Lyzeum
#9	PathAI	#26	Sciento	#44	Aiforia	#62	BARCO
#10	ZAYA AI	#27	Vizgen / Ultivue	#45	Mindpeak / Zeiss	#63	Axlab
#13	Viseur AI Biogenlab	#28	Cytario	#46	SCC Soft Computer	#65	Epredia
#14	Dell Technologies	#29	NPIC	#47	Histomography	#67	AIRA Matrix
#15	Visiopharm	#30	Hamamatsu	#48	Medica		
#16	CellPath	#31	Tribun Health	#50	NXCT 3D X-ray Histology		
#17	Objective Imaging	#32	GE Healthcare	#51	Source LDPath		
#18	Jusha Medical	#36	Excilone	#52	PATHQA		
#19	Sectra	#37	Techcyte	#53	PAICON		

*Global Engage reserves the right to make adjustments to this plan where necessary for operational reasons

Sponsored by:



Tuesday 9th December 12:00-16:00 - Room Richmond 1 & 2

Complimentary access but registration is required & subject to approval by Indica Labs

[Click Here to Register for the Workshop](#)

Indica Labs' London HALO® User Group Meeting



Indica Labs is pleased to announce our London HALO® User Group Meeting at Hilton London Metropole on 9 December from 12:00-16:00. A lunch will be provided to all pre-registered attendees, and a drinks reception will follow the event from 16:00- 17:00.

Our program this year features three excellent guest speakers representing leading universities, digital pathology consortiums, and medical centers who will discuss how they use products and services from Indica Labs to meet their digital pathology goals. Our partners at Molecular Instruments will also join us to share the latest developments in their imaging products and how they integrate with HALO image analysis. In addition to our guest speakers, Indica Labs will present on our latest advancements in image analysis, image management, and services and our collaborative work with our partner Leica Biosystems.

We welcome anyone who is interested in learning more about Indica Labs' quantitative digital pathology solutions to register for the meeting. You do not need to be a current Indica Labs customer to attend.

11:00-12:00	Registration / Lunch Pick Up
12:00-12:10	 Katie McKinley VP, Clinical Applications, Indica Labs Welcome Address
12:10-12:30	 Fatlum Hasaj Applications Specialist, Clinical, Indica Labs Embedding HALO and HALO AI into HALO AP® Workflows This session will explore how embedding HALO and HALO AI into HALO AP® enables teams to share AI algorithms with pathologists in a controlled, review-ready environment. Whether automated or manually triggered, these tools are designed to be "ready-to-run," offering unmatched flexibility for diverse workflow requirements.
12:30-12:50	 Dr. Peter Caie Sr. Principal Scientist, AI Diagnostics, Indica Labs Overview of Indica's HALO Clinical AI and Future Roadmap This presentation will give an overview of our current HALO Clinical AI portfolio. We will cover the products and our development and validation strategies. The talk will also give an overview of our future roadmap and collaborative work with our partner Leica Biosystems. During the talk, you will: - Understand the current HALO Clinical AI portfolio - See how we develop and validate our products - Learn what is coming next in the Clinical AI field for Indica Labs
12:50-13:20	 Dr. Reuben Borg Consultant Pathologist, Mater Dei Hospital A Seamless Digital Transformation with HALO AP® and LIMS Integration This presentation outlines the deployment of our digital pathology system, focusing on the system selection process, the parallel implementation of a new laboratory information management system (LIMS), and the seamless integration of both platforms. The session will review the challenges and successes of the tendering phase, highlighting how this selection process ensured a robust selection of vendors and technologies. Key topics include the technical and operational integration between HALO AP® and the LIMS, with emphasis on quality control (QC) mechanisms for immunohistochemistry and histology labs. We will discuss how these integrations have streamlined workflows, and improved turnaround times, while maintaining QC standards. The presentation will also explore our current plans to transition to digital requests, eliminating the need for physical slides and paper forms. This shift enables a fully digital workflow, enhancing efficiency, traceability, and collaboration across departments. By sharing our experiences and lessons learned, we aim to provide actionable insights for institutions considering similar digital transformations in pathology.
13:20-13:40	Coffee Break
13:40-14:10	 Dr. Alexander Wright Head of Research Infrastructure, National Pathology Imaging Co-operative, Leeds Teaching Hospitals NHS Trust NPIC's National Digital Pathology Research Platform for NHS Secure Data Environments The National Pathology Imaging Co-operative (NPIC) based at Leeds Teaching Hospitals NHS Trust is working to digitise pathology imaging across England using a centralised PACS environment. As part of this work, an additional dedicated research environment has been created to receive deidentified copies of routine clinical pathology image data for research – supporting projects and collaborations with academics, healthcare professionals and industry partners across the globe. By utilising HALO Link for image management and AI deployment, we are now scaling up our research platform to support NHS Secure Data Environments (SDEs), to supply them with high quality digital pathology data. Supported by the NHS England Data for Research and Development programme, the platform is being built to provide safe access to large imaging datasets - supporting clinical trials, research cohort discovery, and the development of AI tools. This talk will give a background to the NPIC programme, an overview of the infrastructure used to support the demands of both of clinical and research activity, and outline how we are utilising HALO Link to manage large scale digital pathology imaging data from various sources to support a diverse range of research projects.
14:10-14:30	 Dr. Ghislaine Lioux Sr. Field Applications Scientist, Indica Labs Unlock Cell Population Discovery Using HALO High Dimensional Analysis With multiplexed imaging now routine in digital pathology, extracting meaningful insights from complex datasets is more crucial than ever. Without advanced tools capable of handling numerous biomarkers, key phenotypic patterns and novel cell populations could easily go unnoticed. The HALO High Dimensional Analysis module addresses this need by seamlessly integrating dimensionality reduction and unsupervised clustering into an intuitive software ecosystem. During the talk, you will: - Understand the challenges of analyzing multiplexed imaging data and how high-dimensional techniques address them - Learn how clustering and dimensionality reduction workflows operate within HALO - See how the module's dynamic link back to original images enables you to validate discoveries in their precise spatial context
14:30-15:00	 Dr. Bilal Mohamad El-Masri Postdoctoral Researcher, Dept. of Pathology, Odense University Hospital/Dept. of Clinical Research, University of Southern Denmark, Odense Denmark Leveraging HALO and HALO AI for Spatial mRNA Expression Analysis in Bone Tissue Understanding how bone cells coordinate the activation of bone-degrading osteoclasts is key to advancing treatments for skeletal disorders. In this presentation, Bilal El-Masri demonstrates how HALO and HALO AI were used to analyze the spatial mRNA expression of key cytokines and uncover the cellular mechanisms driving osteoclast activation. By combining single- and multiplex in situ hybridization with AI-powered image analysis, spatial expression patterns of cytokine mRNAs were quantified and mapped across bone compartments. Contrary to long-standing assumptions that matrix-embedded osteocytes act as primary activators, the spatial data revealed that bone surface cells predominantly express activating cytokines, while inhibitory cytokine signals originate mainly from embedded osteocytes. Through precise cell classification, quantification, and spatial mapping, HALO provided the analytical power needed to visualize complex cytokine signaling within bone tissue. This work highlights how HALO and HALO AI can transform tissue-based research by providing deeper biological insight and enabling new discoveries in spatial biology.
15:00-15:20	Coffee Break

**Dr. Aneesh Acharya**

Chief Commercial Officer, Molecular Instruments

Quantitative In Situ Analysis with HCR™ RNA and Protein Imaging: Expanding Discovery with HALO

HCR™ products enable high-performance, quantitative visualization of RNA and protein targets directly within FFPE tissue. This presentation will highlight recent advances in the HCR™ platform—including the HCR™ HiFi Encoder for next-generation multiplex protein imaging and short-target detection chemistry for RNA analysis—that expand the scope of in situ workflows across research and translational applications. Together, these chemistries deliver multiplexed, background-suppressed detection with high signal fidelity and compatibility across diverse tissue types and fixation conditions.

We will demonstrate end-to-end workflows integrating HCR™ Imaging with Indica Labs' HALO software for automated quantification and spatial analysis of RNA and protein expression. These methods support reproducible, data-rich insights at cellular resolution and enable comparative studies across targets and tissue contexts.

This session emphasizes practical applications and analytical integration, focusing on strategies for generating high-quality, quantitative imaging data from FFPE samples using combined HCR™ and HALO workflows to support biomarker discovery and validation in tissue-based research.

15:20-15:40

**Doug Bowman**

VP, Pharma Services, Indica Labs

Pharma Services: AI-powered, Quantitative Image Analysis Services from Discovery to Clinical Trials

Our Pharma Services team is an experienced multidisciplinary team that develops AI-powered image analysis workflows to support your preclinical and clinical studies. Building image analysis and AI solutions to support these studies requires multi-subject matter expertise and considerable resources. Developing a strategy that involves a combination of in-house resources and outsourcing allows customers to focus on the key scientific questions to drive their biomarker studies forward.

This presentation will provide a brief introduction of the group, introduce new capabilities, and highlight two AI workflows: analysis of ADC target expression and bystander effect, and workflows for scaling AI training using ground-truth annotations from same section mIF or IHC panels.

15:40-15:55

**Katie McKinley**

VP, Clinical Applications, Indica Labs

Closing Remarks

15:55-16:00

16:00-17:00

Drinks Reception

8:00-8:45

aignostics

Registration - Lanyards Sponsored by Aignostics

8:50-9:00

Room: Kensington

Global Engage Welcome Address & Morning Chair's Opening Remarks

Room: Richmond 5 & 6

Room: Richmond 1 & 2

Chair: Tim Bracey, Consultant Pathologist, Royal Cornwall Hospital**Chair: Peter Clements**, Executive Director, Global Head of Pathology, GSK**KEYNOTE ADDRESS:****DARREN TREANOR**

Consultant Pathologist, Clinical Professor of Pathology, Adjunct Professor of Digital Pathology, Director, Leeds Teaching Hospitals NHS Trust, University of Leeds, Linköping University, National Pathology Imaging Co-operative

Digital pathology and AI in 2025: An update from the National Pathology Imaging Cooperative

Pathology is digitising rapidly, and the capabilities of AI are increasing all the time. Against this background I'll give an update on the UK National Pathology Imaging Co-operative, which has taken a strategic centralised national approach to digital pathology in the NHS. On the clinical side, NPIC has welcomed new member sites in 2025, with over 250 pathologists at 11 Trusts now seamlessly linked on a single powerful and secure national PACS system. Over 2.5 million images are being scanned per year in one of the largest digital pathology networks in the world. The system supports our national pathology network for paediatric tumours. A unique secure data environment for pathology research has been established, supporting a number of projects nationally and internationally. Work has continued to enable artificial intelligence across the whole lifecycle from model development through to deployment, including our ENSURE-AI program to independently evaluate AI models on NHS data, accelerating the safe adoption of AI in the NHS.

KEYNOTE ADDRESS:**ALEKSANDRA ZURAW**

Founder, Digital Pathology Place, Veterinary Pathologist, Charles River Laboratories

From Curiosity to Confidence: Empowering Digital Pathology Trailblazers to Lead the Way

Digital pathology adoption is often seen as an infrastructure challenge - but technology is only half the story. The deeper barrier is hesitation: the belief that without immediate access to scanners or platforms, there's no point in learning. In reality, knowledge drives adoption, not the other way around. Education can level the field with little to no investment, ensuring that when the "perfect storm" of affordability and organizational readiness arrives, professionals are ready to leverage it fully. Drawing on insights from thousands of professionals engaging with Digital Pathology Place through courses, e-books, podcasts, and community resources, this keynote will outline what today's trailblazers know, what holds others back, and why peer-to-peer leadership is essential to accelerate adoption.

Key takeaways:

- Why knowledge - not infrastructure - must lead adoption
- What industry insights reveal about barriers and progress
- The role of trailblazers and vendors in guiding hesitant adopters

JAN VON DER THUSEN

Consultant Histopathologist, Erasmus MC

SECTRA
*Knowledge and passion***KEYNOTE ADDRESS:****ARTHUR LEWIS**

Director of Pathology, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca

Enabling Large-Scale Preclinical AI: AstraZeneca's Global Digital Pathology Workflow and Standardized WSI Repository

- AstraZeneca has developed a comprehensive Digital Pathology Imaging & Omics (IO) Platform that automates ingestion and centralized storage of whole slide images (WSI) and metadata from direct from global internal discovery labs and external CROs, supporting portfolio-wide preclinical study evaluation, applying quantitative AI image analysis and efficient pathologist digital assessment.
- The IO Platform incorporates a robust workflow to prepare anonymised WSI and incorporates alignment of associated SEND (Standard of Exchange of Non-clinical Data) datasets.
- This enabling capability is critical to the delivery of our accelerated retrospective preclinical study digitization project, creating an integrated dataset of ~ 500,000 WSI from non-clinical toxicology slides. This will enable large-scale preclinical pathology foundational model development, accelerating and enhancing drug research and development.

KEYNOTE ADDRESS:**MONIKA LAMBA SAINI**

Global Translational Pathology Leader, ADC Therapeutics, Education Committee, Digital Pathology Association

Leveraging Digital Pathology and AI for ADCs and drug development

Digital pathology is creating a vital link between drug discovery, translational research, and clinical trials, especially as the number of clinical trials for precision medicine and next-generation therapies continues to grow. Artificial Intelligence (AI) applications and platforms are currently being utilized across various stages of drug development and discovery from the initial target identification to indication selection, patient stratification to companion diagnostics, and post-marketing oversight, covering the preclinical, clinical, and manufacturing phases. Digital pathology and AI are being leveraged to improve patient enrolment and endpoint evaluation, as seen with the recent FDA approval of an ADC companion diagnostic in prospective clinical trials. Drawing on her extensive experience across both CRO and pharma landscapes, Dr. Lamba Saini will highlight important considerations for the effective implementation of digital pathology and AI to accelerate drug development to deliver innovative treatments to patients.

10:45-11:55

Room: Kensington

Morning Break / Poster Presentations / One-to-One Partner Meetings

Room: Richmond 5 & 6

IMAGING AI & DIGITAL IMAGE ANALYSIS

Chair: Tim Bracey, Consultant Pathologist, Royal Cornwall Hospital**MANUEL SALTO-TELLEZ**

Professor of Integrated Pathology & Director of the Integrated Pathology Unit, Institute of Cancer Research & Royal Marsden Hospital, London, Professor of Molecular Pathology & Director of the Precision Medicine Centre, Queen's University Belfast

Digital Pathology & Integration in multi-modal analysis

- The field needs complex biomarkers to match the biological complexity of cancer and new drug agents
- In tissue analysis, this complexity is achieved in 3 ways: a) by extracting more information to basic images (e.g. AI applied to H&Es); by generating more complexity (for instance, by applying mIF technology to tissue hybridization); or c) by integrating tissue analysis to other high-throughput technologies (multimodal analysis)
- In this lecture, we will illustrate each of these avenues with work from our laboratories and others.

11:55-12:20

**ALEXANDER WRIGHT**

Head of Research Infrastructure, National Pathology Imaging Co-operative

Enabling Imaging AI: Infrastructure and Secure Data Environments for Scalable Deployment

NPIC is building infrastructure to support deployment of AI in digital pathology in the NHS at a national scale. This talk will focus on the development of our Secure Data Environment (SDE) platform, designed to enable access to high value imaging data for AI research and validation, leading to clinical integration. By establishing robust pipelines for data extraction and processing, we are laying the groundwork for AI integration in our national clinical PACS. The presentation will outline how this infrastructure supports future AI deployment across NPIC partner Trusts, as well as research and innovation in healthcare.

12:20-12:45

**CHAITH KONDRAGUNTA**

CEO, AIRA Matrix

ORLY ARDON

Director Digital Pathology Operations and Assistant Attending, Memorial Sloan Kettering Cancer Center

Quality Control Automation for Accuracy and Efficiency in Computational Pathology Workflows

Digital pathology solutions are gaining traction in laboratories globally. For these solutions to be sustainable in real-world applications, it is crucial to identify tools that effectively automate digital workflows and lay the groundwork for advanced AI-based image analysis. AIRAQc is one such quality control solution designed for pre-analytical anatomic pathology workflows that delivers both these benefits. It automates the detection and quantification of processing and scanning errors early in the workflow, which helps reduce costs, accelerates turnaround times, and ensures clean digital image data. This also significantly improves the accuracy of downstream AI-based image analysis. We will be presenting a case study on the enterprise-level

12:45-1:15



Room: Richmond 3 & 4

CHALLENGES WITH IMPLEMENTATION, WORKFLOW, & STANDARDISATION

Chair: Bobbi Pritt, Chair of Clinical Microbiology, Mayo Clinic, USA**BOBBI PRITT**

Chair of Clinical Microbiology, Mayo Clinic, USA

AI in Action: Transforming Image-Based Clinical Pathology
This presentation will discuss how AI is revolutionizing image-based analysis in clinical pathology. Using real-world examples from the Mayo Clinic clinical microbiology laboratory, we will highlight examples of AI-assisted workflows and discuss the impact on clinical care, staff satisfaction, and laboratory efficiency.

11:55-12:20

**CELINE DEGALLIER**

Scientific Collaborator, Anatomic Pathology Department, University Hospital Brussels

WIM WAELPUT

Senior Pathologist, University Hospital Brussels

Challenging Financial and Technical Limits: Practical Experiences and Lessons-Learned in Pathology Imaging Data Storage Management

This presentation shares practical experiences from the pathology department in managing data storage and archiving, especially with a focus on imaging data. As these volumes have grown exponentially, the department repeatedly faces limitations in the hospital's storage infrastructure especially in an environment with limited financial resources. Despite these constraints, several opportunities emerged that helped guide the development of more efficient and sustainable storage specifications. These experiences offer valuable insights into what needs to be considered when building a durable and future-proof storage management strategy. The talk aims to share lessons learned and encourage a discussion around best practices.

12:20-12:45

**DONAL O'SHEA**

PhD, Chief Executive Officer, Deciphex/Diagnexia

Faster, Better Diagnostics: Practical AI Applications in Pathology Services

The pathology diagnostics sector faces global capacity challenges due to subspecialist shortages. This presentation outlines practical AI implementations improving diagnostic efficiency across NHS trusts and international systems. Workflow automation such as OCR-based data extraction, automated case assembly, and AI-driven subspecialty triage reduces administrative bottlenecks while maintaining PHI compliance. Foundation models trained on millions of pathology images support risk assessment, quality assurance, and biomarker discovery, enhancing diagnostic accuracy and consistency. Real-world deployment shows measurable reductions in turnaround time and improved diagnostic reliability. This framework offers healthcare organizations practical strategies for safe, scalable AI adoption in pathology, supporting sustainable service delivery without compromising quality.

12:45-1:15



Room: Richmond 1 & 2

DIGITAL PATHOLOGY & AI IN PHARMA

Chair: Peter Clements, Executive Director, Global Head of Pathology, GSK**ELENA MIRANDA**

Director, Non-Clinical Histology, GSK

Advancements in Modern Histology: Computational Staining and 3D Histology

Traditional 2D histology involves sectioning tissues into thin slices, staining with chemicals or antibodies and examining them under a microscope. While effective for many applications, this approach is laborious and can miss crucial spatial information and complex three-dimensional structures. Advancements in computational staining and 3D histology have revolutionized the field of histology, providing a more comprehensive understanding of biological tissues along with more sustainable, rapid, and cost-effective alternatives to conventional histology. However, their development is still in the early stages and requires thorough validation. As technology continues to advance, the potential applications and impact of these new approaches will only expand, promising exciting developments in the years to come. This presentation provides an overview of recent developments in the field, along with examples from projects.

11:55-12:20

**BARKHA GUPTA**

Senior Medical Pathologist, Sanofi

Opportunities & challenges of utilizing digital pathology analysis in clinical trials

Artificial intelligence (AI)-assisted digital pathology is rapidly emerging as an integral component of modern pathology services across hospital, research, and pharmaceutical settings. A wide range of digital workflow algorithms and image analysis platforms now enable pathologists to achieve enhanced performance, quantitative outputs, and whole-slide analysis with greater precision. The integration of digital pathology into clinical trials, however, introduces a complex landscape of regulatory considerations, which vary depending on the intended use of the assay. Anticipating and understanding these regulatory frameworks is critical for mitigating challenges and ensuring successful implementation in clinical development. This presentation will discuss the opportunities and challenges of AI-driven digital pathology in clinical trials, with a particular focus on regulatory compliance strategies that support innovation while maintaining scientific and clinical rigor.

12:20-12:45

**MARION GEERLIGNS**

Digital Pathology Category Leader, Philips

Integrated diagnostics: From complexity to clarity in prostate cancer care

Workforce shortages, clinician burnout, and rising patient demand are putting pressure on care providers - especially in radiology and pathology. Prostate cancer, one of the most common malignancies worldwide, adds complexity with challenges in detection, diagnosis, and treatment planning. Join this session to discover how AI and other innovations in radiology, pathology and urology can transform the prostate cancer care pathway. You'll learn:

- How AI-enhanced MRI reading improves diagnostic efficiency and accuracy and streamlines PIRADS-compliant reporting.
- Ways image-fusion-guided biopsy reduces unnecessary procedures and supports urologists in precision care.
- How digital pathology and AI-driven interpretation boost efficiency and

12:45-1:15



12:45-1:15	deployment of AIRAQc within multispecialty, high-throughput workflows, highlighting improvements in accuracy and workflow efficiency.	12:45-1:15	Continued	12:45-1:15	alleviate workforce strain. The benefits of integrating multimodal data for personalized focal therapy planning. Explore how these advancements deliver faster, more accurate diagnoses and connected care for men's health.
1:15-2:25	Room: Kensington	Lunch			
	Room: Richmond 5 & 6		Room: Richmond 3 & 4		Room: Richmond 1 & 2
2:25-2:50	Chair: Paola Anghileri, EMEA Commercial Development Leader DP, Leica DAVID SNEAD Professor & Consultant Pathologist, Director, University Hospitals Coventry & Warwickshire NHS Trust, PathLAKE, Warwick Medical School Coventry Emerging Roles for Large Language Models and Agentic AI in Cellular Pathology A large language model is an advanced type of artificial intelligence (AI) trained on large amounts of text data to understand context and generate human-like language. These models are based on deep learning, and are capable of: - Understanding natural language input (e.g., questions, instructions) - Generating coherent, context-aware responses - Summarizing, translating, or explaining complex concepts - Reasoning across documents and modalities (in more advanced models) Agentic AI refers to artificial intelligence systems that act as autonomous agents entities capable of making decisions and taking actions in pursuit of defined goals with or without human intervention. Systems using human in-put are often presented as conversational solutions which modify results given secondary inputs from the operator. These systems are designed to plan, reason, and adapt to dynamic environments, often interacting with humans, tools, or other AIs to complete complex tasks. This technology has begun to be presented as aids or co-pilots to pathologists particularly in case reporting, but other uses are emerging particularly in the management of large volumes of research data in toxicological pathology and in quality management systems where time consuming routine tasks can be automated and important efficiencies can be realised, particularly in laboratories grappling with short staffing. This presentation reviews the way this technology is being used currently and expands the horizons to what is coming next.	2:25-2:50	Chair: David de Mena, Global Digital Pathology IT Content Manager, Leica ELIZABETH NEYENS Principal Consultant, Toxicologic Pathologist, ElizabethToxPath Consulting Inc Return on Investment When Implementing Digital Pathology in Pharma & Consultancy Strategic ROI: How to Justify and Monetize Digital Pathology - Build the business case: cost-saving on logistics, faster turnaround, global expert access - Show ROI with case studies (e.g. reduced repeat pathology, enhanced collaboration) Client Education & Adoption: Building Trust in Digital - Tactics for client buy-in pilot studies, side-by-side validation, visual impact Addressing common concerns: image quality, regulatory acceptance, and diagnostic reliability GLP and Regulatory Considerations: Extra Work or Smart Integration? - Dos and don'ts for GLP compliance (audit trail, image archiving, validation) - Clarify when extra documentation or validation is required for digital workflows Operational Bottlenecks and Scaling: From Slide Scanning to Communication - Lab readiness, scanning QC, IT infrastructure (bandwidth, storage, viewer compatibility) - Managing turnaround with offsite pathologists, time zones, and secure communications Confidentiality, IP, and Consultant Collaboration Models - Data security in cloud platforms; NDAs and access management - Charging models: per-slide, per-project, or time-based; handling pre-review or draft reporting	2:25-2:50	Chair: Olga Colgan, Strategic Marketing Director - Digital Pathology, Leica ERIO BARALE-THOMAS Senior Principal Scientist, Pathobiology, Johnson & Johnson AI-based detection of cellular alteration foci in rat liver During the review of a 6-month rat study performed outside J&J, the J&J reviewing pathologist noted tigroid basophilic foci of cellular alteration in the liver at a higher incidence than what was recorded by the original study pathologist and in all treated groups. Foci of cellular alteration are a localised proliferation of hepatocytes, well characterised in toxicology pathology (Thoolen & al., 2010, 10.1177/0192623310386499). However, they can be difficult to detect because of their small size and phenotypic and tinctorial properties (with several subtypes). Some of the subtypes may be spontaneous and age-related, but also chemically induced or preneoplastic. These characteristics motivate why a precise identification of foci of cellular alteration is warranted. Our objective was thus to develop an AI algorithm to rapidly quantify basophilic tigroid foci with high sensitivity to aid analysis performed by the toxicologic pathologist. During the presentation, we will present the data set used, annotation strategy for positive and negative examples, and the algorithm's performance compared against manual assessment by the pathologist. We will discuss the amount of foci uncovered by the algorithm beyond the manual assessment, and the false negative and positive rates, highlighting its benefit as a screening tool. We will conclude with our deployment strategy and benefits of this model for the pathologist.
2:50-3:15	MANU SEBASTIAN Professor, University of Texas MD Anderson Cancer Centre Applications & Challenges of Utilising Digital Pathology & AI in Clinical Trials This talk will provide a detailed overview of the key differences between diagnostic pathology and clinical trials, highlighting how their distinct goals, workflows, and regulatory frameworks shape the role of tissue analysis in each setting. The talk will discuss the integration of computational pathology into clinical trial design and execution, with an emphasis on how these methods enable the development and validation of tissue-based digital biomarkers. Additionally, we will discuss the advantages of digital pathology for modern global clinical trials. The presentation will also showcase multiple computational pathology applications, featuring concrete examples of how algorithm-driven tissue analysis can support patient stratification and precision-medicine-driven clinical trials.	2:50-3:15	IAN MASON Programme Head, Digital Deployment & Business Services, National Pathology Imaging Co-operative (NPIC) USMAN ARIF Programme Head - Digital, Data & IT Services, National Pathology Imaging Co-operative (NPIC) Digital Pathology Implementation, Strategy & Application - The NPIC Journey Digital pathology represents a transformative shift in histopathology, replacing traditional glass-slide methods with fully digital workflows. Led by the National Pathology Imaging Cooperative (NPIC), which pioneered the first 100% digital histopathology service at Leeds Teaching Hospital in 2018, the NPIC digital pathology platform now connects multiple hospitals across England, driving implementation, training, validation, and innovation. Despite technical, operational, and cultural challenges, NPIC's experience highlights the importance of collaboration, leadership, and ongoing support. DP enhances diagnostic accuracy, education, and quality assurance, while enabling remote reporting and AI integration reshaping pathology services and advancing patient care through digital transformation.	2:50-3:15	PETER GROSS Principal Scientist, Boehringer Ingelheim MASH Explorer - AI-based segmentation of rodent livers We present a custom AI designed to analyze MASH-relevant pathological features in whole-slide images of rodent livers from preclinical studies. Trained on a diverse in-house dataset spanning multiple liver damage models (e.g., APAP, CCL4, CDAA, TAA, HFD, PHx), the AI identifies more than ten histopathological classes, including healthy and damaged hepatocytes, steatosis, inflammation, and various pathologically relevant collagen patterns. It enables detailed quantification of features such as hepatocyte nuclei size, mitotic events, steatotic vesicles, inflammatory foci, and bridging collagen bundles. This tool supports in-depth characterization of liver pathology and enhances model evaluation in preclinical research.

**SHOKO VOS**

Consultant Pathologist, Radboud University Medical Center

JOJANNEKE DROGT

Medical Ethicist and Postdoctoral Researcher, University Medical Center Utrecht

**Making pathology ready for the new AI era**

Progress in artificial intelligence (AI) development has sparked enthusiasm for its application in pathology. For the successful integration of AI in pathology practices, it is crucial to explore the perspectives of pathologists and other professionals working in the field regarding AI use. We therefore highlight how pathologists believe AI can be most effectively integrated into their daily workflows. Moreover, not only are their perspectives important, but adequate training of (future) pathologists is also essential for successful AI use in pathology. We evaluated which entrustable professional activities and competencies pathologists require to make responsible use of AI in daily practice. Pathologists' clinical expertise to interpret AI outcomes in the individual patient's context is crucial for adequately applying AI techniques and communicating its results for patient care. We hope that our analysis can serve pathology training programs to make pathologists fit for a future with AI.

3:15-3:40

IMAGING AI & DIGITAL IMAGE ANALYSIS

**FRIEDRICH PREUSSER**

Principal Image Data Scientist, Vizgen

Spatial Multi-Omics in Tumor Biology: MERFISH, ISP, and Integrated Insights

This session will introduce two complementary spatial technologies MERFISH spatial transcriptomics and ISP multiplex immunofluorescence and show how their integration links transcriptomic and proteomic measurements to define spatially structured biological states. You'll learn:

- How ISP provides multiplexed immunofluorescence staining at scale. You will also learn how the STARVUE AI image analysis platform supports this workflow by delivering robust quantification across diverse tissue types and sample conditions.
- How MERFISH spatial transcriptomics profiles high-plex gene expression in intact tissues, enabling discovery of cellular states, transcriptional programs, and spatial organization across a wide range of biological systems.
- How each modality independently reveals complementary aspects of tissue biology, from transcript-defined cell states to protein-based morphology, structure, and region-level annotation.
- How integrated MERFISH-ISP analyses uncover coherent gene-protein relationships, including spatial correlations and region-specific signatures in tumors, demonstrating the added value of multimodal data integration.

3:40-4:10

**DEBRA PADGETT**

Clinical Pathology Lead & Lead Healthcare Scientist, Northumbria Healthcare NHS Foundation Trust, NENC Pathology Network Operational Lead

Optimising workflow in digital pathology

This talk presents practical strategies for streamlining digital pathology workflows, from slide scanning to AI-assisted reporting. We'll share real-world examples showing how automation, integration, and human/AI collaboration reduce turnaround times, improve accuracy, and boost efficiency. Key considerations include regulatory compliance, infrastructure scalability, and user adoption strategies.

3:15-3:40

CHALLENGES WITH IMPLEMENTATION, WORKFLOW, & STANDARDISATION

**JAMES THACKERARY**

Chief Executive Officer, Lumea

From Promise to Practice: Overcoming Barriers to Digital Pathology Implementation and Standardization

Digital pathology has advanced far beyond the proof-of-concept stage, yet many labs still face significant hurdles in implementation, workflow integration, and achieving true standardization. In this session, Lumea shares practical insights from more than a decade of pioneering digital pathology adoption at scale. Drawing from real-world experience as the U.S. leader in primary clinical digital diagnoses, we'll explore the key obstacles that can slow or stall adoption, from inconsistent workflows and data variability to resistance to change. Attendees will see proven strategies for streamlining tissue-to-diagnosis processes, leveraging AI effectively, and creating standardized, scalable systems that deliver measurable improvements in accuracy, efficiency, and patient outcomes. Learn how to move beyond the buzz to create a truly operational and standardized digital pathology ecosystem.

3:40-4:10

**LUISA BELL**

Neuropathology Scientist, Roche

From Organoid to Algorithm: A Digital Pathology Approach for Preclinical Toxicity Testing using Blood-Brain Barrier Organoids

Complex in vitro models (CIVMs) offer an unprecedented opportunity to support enhanced preclinical to clinical translation by generating high-quality mechanistic data in human in vitro models, i.e. validated Blood-Brain Barrier (BBB) organoids can facilitate effective testing of brain-targeting drugs early in discovery. In this talk, I will present our approach using advanced histotechniques and AI-based image analysis to enhance drug development. We utilized BBB organoids for preclinical toxicity and efficacy screening by adapting standard histopathology workflows to CIVMs. This enables comprehensive model characterization and spatial compound evaluation. Secondly, our high-resolution AI algorithm for single-cell toxicity provides a robust and high-throughput alternative for preclinical screening for apoptosis/necrosis (e.g. killing assay). Taken together, this end-to-end histopathology and digital pathology workflow accelerates decision-enabling experiments by offering a label-free, high-throughput, and reproducible method for evaluating apoptosis/necrosis in BBB organoids, a platform that can be transferred to other organoid models in the future.

3:15-3:40

DIGITAL PATHOLOGY TOOLS & TECHNOLOGIES & ROUNDTABLE DISCUSSIONS

**LORCAN SHERRY**

Chief Scientific Officer, OracleBio

OracleBio's FTE service model: Providing an outsourcing model to Pharma to deliver high quality data whilst strengthening the sponsor's internal digital pathology capabilities

The traditional fee for service outsourcing model lacks the flexibility with respect to time and budget to address novel or complex questions often encountered in image analysis R&D projects. Key learnings such as optimal algorithm development and workflow efficiencies are rarely shared back to the sponsor. OracleBio has introduced a FTE (Full Time Equivalent) resource service model to provide sponsors access to trained image analysis expertise from a pool of specialists. The resource allocation can be aligned to individual project needs, with the sponsor retaining internal control over scientific direction and delivery. This presentation will highlight the implementation of FTEs within Pharma's digital pathology groups and will include image analysis case study examples demonstrating the values of the integrated and collaborative working relationship it fosters.

3:40-3:55

**MICHAEL VALANTE**Global Business Lead, Healthcare and Life Science UDS, CTO, Digital Pathology, Dell Technologies
The Dell AI Data Platform in Medicine: Advancing Digital and Computational Pathology, Clinical Imaging and Research

This session will provide an understanding of the Dell AI Data Platform, a scalable solution designed to support advanced analytics, data science and emerging AI scenarios for data-intensive healthcare use cases such as digital and computational pathology, clinical imaging, and medical research. It enables seamless ingestion, processing, and storage of diverse datasets, including digital imaging, genomics, and clinical trial data. With advanced data engines, it streamlines workflows, enhances unstructured data searchability, and automates data management, ensuring secure and efficient handling of sensitive patient information at scale. By optimizing resources and enabling real-time decision-making, it empowers clinicians and researchers to improve diagnostics, accelerate innovation, and advance personalized medicine.

3:55-4:10



4:10-5:00

Room: Kensington

Afternoon Break / Poster Presentations / One-to-One Partner Meetings

Room: Richmond 5 & 6

Chair: Paola Anghileri, EMEA Commercial Development Leader DP, Leica

**CHRISTOPHER MILLS**

Senior Scientist, Concept Life Sciences

PhenoScout: Foundation AI Models for End-to-End Tissue Analysis of mIF and IHC Slides

Digital pathology has enabled high-throughput, remote analysis of stained tissue slides for research and diagnostics. However, AI-based analysis tools have lagged, especially for complex staining protocols like multiplex immunofluorescence (mIF). Key challenges include heterogeneous antibody panels and difficulty generalizing algorithms across different chemistries. To address this, we present a novel end-to-end workflow combining ZEISS AxioScan 7 spatial biology, SlideStream scan automation software, and Mindpeak's PhenoScout AI system. At the core is PhenoScout, a library of foundation AI models designed for tissue analytics across wide variety of mIF and IHC stainings, requiring no prior image analysis experience.

5:00-5:15

**MANASI AICHMUELLER-RATNAPARKHE**

Co-Founder & CEO, PAICON GmbH

Global Data. Precise Diagnostics - When Data Lacks Diversity, Diagnosis Lacks Precision

PAICON tackles a critical flaw in AI-driven cancer diagnostics: the exclusion of 84% of the global population from training data. This lack of representation leads to biased algorithms, missed biomarkers, failed clinical trials, and an estimated \$5 billion cost of exclusion. PAICON's curated, multimodal datalake built from over 130,000 cases across 60+ countries integrates genetically and technically diverse, real-world cancer data to power inclusive AI models that perform across populations. By reducing bias and expanding representation, PAICON improves diagnostic accuracy, supports more reliable drug development, and sets a new standard for equity in global healthcare.

5:15-5:30

PANEL DISCUSSION:**When Value Networks Shift: What Disruptive Innovation Means for NHS Pathology****SIDNEY OCANAGIL-TUNSTALL** (Chair)

Marketing Director, Pathology News

**BRANKO PERUNOVIC**

Chief Medical Officer, Black Country Pathology Service, (BCPS), Royal Wolverhampton NHS Trust

**DAVID CLARK**

Consultant Pathologist, Nottingham University Hospitals NHS Foundation Trust

Disruptive Innovation - the clue is in the name - does not sustain or improve pre-existing delivery models, it creates an entirely new value network with operating and business models that replace what went before. The disruptive innovation cycle has played out countless times sweeping aside the dominant providers in transport, telecommunications, computing, retail and entertainment. Why should healthcare be different?

5:30-6:20

Room: Richmond 3 & 4

Chair: David de Mena, Global Digital Pathology IT Content Manager, Leica

SENIOR REPRESENTATIVE

Jusha



5:00-5:30

**MAC (ROBERT) MACAULAY**

Pathology LIMS Manager, Deputy Head of Pathology IT, DHP SME, Pathology IT and Transformation, University Hospitals Sussex NHS Foundation Trust

DHP implementation within the Sussex Pathology Network - lessons learnt and technical blockers

This session shares the real-world experience of launching Digital Histopathology across Network South 7 - The Sussex Pathology Network. We'll explore workflow redesign, practical lessons learnt, common pitfalls, and strategies to deliver safer, faster digital adoption in the NHS.

5:30-6:55

Room: Richmond 1 & 2

Chair: Olga Colgan, Strategic Marketing Director - Digital Pathology, Leica

**ADAM LEVINE**

Academic Consultant Pathologist, UCL and UCLH

**JON GRIFFIN**

Senior Clinical Lecturer and Honorary Consultant Histopathologist, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust

Do AI-powered workflows enhance MMR/MSI testing for colorectal cancer? A deep dive into findings from two NHS hospitals

Join us to learn first-hand how our MSIntuit-CRC solution transforms microsatellite instability (MSI) testing in colorectal cancer with advanced AI for digital pathology. Drawing on retrospective studies from two major NHS hospitals (University College London Hospital and Sheffield Teaching Hospital), our innovative approach integrates AI-based screening for MMR/MSI status into the pathology workflow for colorectal cancer samples.

5:00-5:30

ROUNDTABLE DISCUSSIONS:**Table 1:****Adoption Starts with Education: Empowering Future Users, Vendors, and Trailblazers****ALEKSANDRA ZURAW**

Founder, Digital Pathology Place, Veterinary Pathologist, Charles River Laboratories

**Table 2:****Challenges of Computational Pathology Application in Precision Medicine****MANU SEBASTIAN**

Professor, University of Texas MD Anderson Cancer Centre

- Application for Patient Stratification in clinical trials
- How Computational Pathology can compete against Radiology/Imaging
- How Computational Pathology can compete against Genomics

5:30-6:20

5:30-6:20

If computational pathology is not a disruptive innovation how can NHS Trusts justify further investment?

If it is disruptive what could the new operating and business models look like and who will provide them?

Will NHS pathology services be disrupted or disrupt themselves?

5:55-6:20



AMAL ASAR
Consultant Histopathologist, Northern Care Alliance

Training and retaining Pathologists in the age of AI - minefields to be wary of!

AI is promising to solve the Pathology staffing bottlenecks, and to make the workplace more interesting for Pathologists. While there are undeniable and indeed tangible benefits that are widely reported at this infancy stage of AI, how would large scale deployment in the years to come alter the Pathology profession and the training for the upcoming generations. Could we reach a position in the future where Pathologists are not scarce, but are actually redundant? I will try to dig deeper and explore this question based on the current staggering AI progress and benchmark that with past experiences.

5:30-6:20

Continued

6:20-6:25

Leica Biosystems Closing Address

6:25



Networking Drinks Reception
Sponsored By
LEICA BIOSYSTEMS

8:55-9:00	Room: Kensington	Global Engage Welcome Address & Morning Chair's Opening Remarks	
	Room: Richmond 5 & 6		Room: Richmond 1 & 2
	Chair: Hugh Risebrow , Co-Founder & Partner, Digital Pathology Partners		Chair: Elizabeth Neyens , Principal Consultant, Toxicologic Pathologist, ElizabethToxPath Consulting Inc
9:00-9:40	 KEYNOTE ADDRESS: LIRON PANTANOWITZ Professor and Chair of Pathology, University of Pittsburgh, USA Computational Pathology as a Strategic Asset: Leadership Lessons from the Frontlines - Explain why I built a Computational Pathology division and why you should too. - Demonstrate why every Pathology Department could benefit from an AI Center - Discuss how our Office of Collaborative Pathology serves as a new model for innovation.	9:00-9:40	 KEYNOTE ADDRESS: LISE BERTRAND Scientific Director, Digital Pathology, Charles River Laboratories Deploying AI in Nonclinical Pathology: Aligning Innovation with Industry Needs Artificial intelligence is reshaping toxicologic pathology, offering powerful tools to improve consistency, throughput, and decision-making in nonclinical drug development. This presentation explores practical strategies for deploying AI across pathology workflows. Case examples will highlight how AI can reduce variability, support digital pathology adoption, and streamline safety evaluations. Emphasis will be placed on aligning AI implementation with operational goals and industry standards to ensure scientific rigor and regulatory acceptance. Attendees will gain a clear understanding of the current capabilities, limitations, and future potential of AI in nonclinical safety assessment.
9:40-10:15	 KEYNOTE ADDRESS: NORMAN ZERBE Head of Digital Pathology Research, Charité - Universitätsmedizin Berlin	9:40-10:15	 RADHA KRISHNAN Head of Clinical Pathology, MSD Machine learning and multi-modal approaches to interrogate Inflammatory bowel disease (IBD) - Endoscopy is the prevailing objective disease activity measurement for IBD, but fails to completely describe bowel injury. Histologic activity is increasingly being shown in both CD and UC to better predict long term clinical outcomes, with prognostic value even in subjects who appear endoscopically normal. - Use Machine Learning (ML) and multi-modal approach on UC and CD datasets with the aim to identify novel prognostic and predictive baseline clinical histological biomarkers associated with patients' response to treatment and disease severity. - Generate insights in fibrosis and profibrogenic pathways by identifying cellular signals that demonstrate correlation with development and progression of fibrosis.
10:15-10:45	 DAVID DE MENA Global Digital Pathology IT Content Manager, Leica AI-Powered Pathology: The Future of Precision Medicine Computational pathology is redefining precision diagnostics through the integration of artificial intelligence and quantitative image analysis. By combining algorithmic precision with pathologist expertise, it enables reproducible, high-resolution biomarker assessment and minimizes observer variability. This presentation will explore the evolution of digital pathology, key milestones in clinical adoption, and how pixel-level quantification and spatial biomarker analysis are advancing companion diagnostics and immunotherapy development. Together, these innovations are transforming diagnostic accuracy, improving equity in patient care, and ushering in a new era of data-driven pathology		
	PANEL DISCUSSION:  DAVID DE MENA (Chair) Global Digital Pathology IT Content Manager, Leica  PETER CAIE Sr. Principal Scientist, AI Diagnostics, Indica Labs  DIANA MONTEZUMA FELIZARDO Pathologist and Head of the R&D Unit at IMP Diagnostics		
10:45-11:35	Room: Kensington	Morning Break / Poster Presentations / One-to-One Partner Meetings	

Room: Richmond 5 & 6

COMPUTATIONAL PATHOLOGY & AI

Chair: Hugh Risebrow, Co-Founder & Partner, Digital Pathology Partners**DIANA MONTEZUMA**

Pathologist and Head of the R&D Unit, IMP Diagnostics

The role of Pathologists in the development of Computational Pathology tools

- Pathologists play a key role in AI development for Pathology, providing the expertise needed to bridge data and clinical application.
- Using practical project examples from IMP Diagnostics, this presentation will illustrate how pathologists can contribute to data curation, annotation, definition of ground truth, and to the critical evaluation of the models' outputs, improving their reliability and clinical relevance.
- This presentation will also explore the value of multidisciplinary collaboration in this setting, and how pathologists can contribute to the integration of AI tools into workflows.

**YURI TOLKACH**

Senior Attending Physician, Research Group Lead, Institute of Pathology, University Hospital Cologne

AI algorithms for Oncological Pathology: Evolution from Diagnostic to Advanced Applications

In my talk, I will share our experience in developing and validating both simple and advanced AI-based tools for pathology and oncology, with a focus on digital pathology applications. I will discuss how the evolution of principles and algorithms in machine learning is reshaping our approach to AI tool development and implementation. Drawing on examples from recent projects to multiple malignant tumours, I will reflect on key bottlenecks such as tumor heterogeneity, data quality, and explainability, and how addressing these will define the future of AI in pathology.

**POSTER COMPETITION WINNER TALK
SUNIL KUMAR MALLICK**

Senior Resident, All India Institute of Medical Sciences, New Delhi

Artificial Intelligence as a Diagnostic Tool: Gastric Cancer Detection and Further Subtyping in Whole-Slide Images**ABHI GHOLAP**

Founder, OptraSCAN, Inc.

AI Powered Whole Slide Digital Scanning Devices

AI-enabled digital pathology scanner designed to revolutionize

slide analysis by integrating scanning, indexing, and real-time biopsy analysis into a single workflow. Unlike conventional scanners that merely digitize slides for post-processing, OS-SiA performs simultaneous image acquisition and predictive analysis, delivering actionable insights during the scanning process. This innovation eliminates the need for separate analytical software, enhancing diagnostic speed and precision. Embedded with deep learning algorithms, OS-SiA supports real-time ROI detection, cell quantification for IHC/HNE markers, and morphological measurements. Compatible with cloud-enabled platforms, it enables seamless viewing and sharing across local, web-based, and cloud environments. The system marks a significant advancement in digital pathology, aiming to accelerate clinical decision-making and improve patient outcomes.



Room: Richmond 3 & 4

CHALLENGES WITH IMPLEMENTATION, WORKFLOW, & STANDARDISATION

Chair: Manasi Aichmueller-Ratnaparkhe, Co-Founder & CEO, PAICON GmbH**PANEL DISCUSSION:****Tackling LIMS Challenges in Digital Pathology****DEBRA PADGETT** (Chair)

Clinical Pathology Lead & Lead Healthcare Scientist, Northumbria Healthcare NHS Foundation Trust, NENC Pathology Network Operational Lead

**JO MARTIN**

Professor of Pathology, Deputy Vice Principal Health, Queen Mary University of London

**NIRAV GANDHI**

Consultant Cellular Pathologist, University Hospitals of Derby and Burton NHS Foundation Trust

**IAN MASON**

Programme Head, Digital Deployment & Business Services, National Pathology Imaging Co-operative (NPIC)

**POSTER COMPETITION WINNER TALK
LORREN MITCHELL**

Scheme Manager, UK NEQAS Cellular Pathology Technique

Implementing a Digital Pathology External Quality Assessment Scheme: A Quality Framework for Diagnostic Image Assessment**CATHERINE GUETTIER**

Emeritus Professor of Pathology Université Paris Saclay - Assistance Publique Hôpitaux de Paris, Consultant for Aiforia Technologies Oyj

**Real-World AI Practice for Pathologists: The Prostate Biopsy Example**

The use of AI in pathology remains limited in routine practice, and many pathologists perceive a clear gap between academic AI research and real-world clinical deployment. While the goals such as reducing reading time and improving diagnostic accuracy are widely shared, the ways these tools are used can differ significantly among pathologists. This presentation draws on the implementation of a prostate biopsy analysis model in two academic pathology departments at APHP, illustrating diverse approaches to integrating AI support into daily workflows. It highlights how individual practices shape adoption and use. Importantly, user experience plays a critical role in discussions with AI developers, helping to identify practical challenges and bridge the gap between algorithm performance and its effective application in real-life pathology settings.

Room: Richmond 1 & 2

DIGITAL PATHOLOGY & AI IN PHARMA

Chair: Elizabeth Neyens, Principal Consultant, Toxicologic Pathologist, ElizabethToxPath Consulting Inc**PANEL DISCUSSION:****AI and Digital Pathology in drug discovery and precision medicine in Pharma****HAKIMA IBAROUDENE** (Chair)

Manager R&D, Southwest Research Institute

**MONIKA LAMBA SAINI**

Global Translational Pathology Leader, ADC Therapeutics, Education Committee, Digital Pathology Association

**ARTHUR LEWIS**

Director of Pathology, Clinical Pharmacology and Safety Sciences (CPSS), AstraZeneca

**LISE BERTRAND**

Scientific Director, Digital Pathology, Charles River Laboratories

**RADHA KRISHNAN**

Head of Clinical Pathology, MSD

**POSTER COMPETITION WINNER TALK
STEPHANIE ROBINSON**

Research Fellow/Beamline Scientist, University of Southampton

Methods of 3D Spatial 'Omics on FFPE Specimens. Example: Human Lung Fibrosis**RYAN POWERS**VP, Global Life Sciences, Aira Matrix
The First End-to-End Unsupervised Learning Platform for Discovery & Safety Pathology

In this session, we will showcase the industry's first and only platform applying true unsupervised learning across all organs and species. This approach brings unparalleled scalability and efficiency to toxicologic and discovery pathology.

Our integrated solution suite spans end-to-end digital image management, automated 'normal vs. not-normal' triage for safety studies, advanced lesion detection and our abnormality quantification, robust quality-control engine, and custom model development for emerging or highly specialized image-analysis needs. We will also highlight our peer review framework and intuitive web-based access that enables the most seamless and transparent workflow.

12:55-1:10	Continued	 CHRIS POLLEY Digital Pathology Business Development Specialist EMEA, Evident Scientific Autonomous Digital Pathology - Efficiency gains in labour, time and costs with Evident technology  The Pramana Whole Slide Imaging (WSI) technology from Evident delivers fully autonomous, adaptive scanning that eliminates rescans and minimizes manual quality control. Through volumetric imaging, in-line quality assurance, and an AI-driven adaptive scan engine, it achieves nearly 100% first-pass success while adapting to diverse tissue and slide conditions. This presentation will outline proven labour, time, and cost efficiencies, demonstrating how autonomous WSI enables scalable, AI-ready digital pathology workflows.	12:55-1:10
------------	-----------	---	------------

1:10-2:20	Room: Kensington	Lunch
-----------	------------------	-------

Room: Richmond 5 & 6		Room: Richmond 3 & 4	Room: Richmond 1 & 2
Chair: Dimitra Pouli , Director of Anatomic Pathology Informatics, Boston Children's Hospital		Chair: Mindaugas Andrusis , Head of Pathology, Klinikum Ludwigshafen	
 DR NICHOLAS SPENCER Global Chief Clinical Information Officer, AGFA HealthCare From Pixels to Precision: Transforming Pathology with AGFA's Enterprise Imaging Suite  Seamless Integration of Digital Histopathology across the Imaging Health Record, Laboratory Information System and other Enterprise-wide applications will be the at the heart of transformation of pathology services. This must build on many facets learned through the protracted digital journey already experienced in radiology. Centralised Image Management, AI Integration and adoption of widely accepted standards for whole slide imaging are just a few of the key components to ensure workflow can be optimised and enable both collaboration and novel dispersed working practices. This presentation will highlight these topics and showcase how Corista and AGFA HealthCare are working together to support efficiency, quality improvement and cost optimisation to ensure return on investment in Digital Pathology.	 PAUL MESANGE Global Director, Histology, Labcorp From Slide to Insight: Modernizing Pathology Workflows for Clinical Trials  Clinical trials depend on digital pathology to accelerate timelines, support global review, and enable emerging biomarkers. Delivering on these goals requires an integrated workflow that reliably moves whole-slide images from scanners to reviewers to downstream analysis without introducing delays or compromising data integrity. This presentation outlines a practical blueprint for modernizing pathology operations through unified image ingestion, cloud transfer, case assembly, and standardized digital review. It also highlights how centralized, file-agnostic storage and scalable compute resources prepare trial data for large-scale analytics, quantitative endpoint development, and future AI applications. By showing how a streamlined digital pathology workflow reduces operational burden while improving consistency and readiness for advanced analysis, this session offers clear guidance for sponsors, CROs, and central labs seeking to modernize trial execution and unlock the full value of image-based data.	Chair: Erio Barale-Thomas, Senior Principal Scientist, Pathobiology, Johnson & Johnson 30-minute Solution Provider Presentation For sponsorship opportunities, contact gavin@globalengage.co.uk	
2:20-2:50	2:20-2:35	2:35-2:50	2:20-2:50
		15-minute Solution Provider Presentation For sponsorship opportunities, contact gavin@globalengage.co.uk	

2:50-3:15

**CHRISTOPHER WALSH**

Research Associate, University of Glasgow, CEO, TileBio Ltd
From Pixels to Words: Unlocking a Visual Language of Pathology

Whole slide images capture extraordinary detail, yet much of their value as AI training data remains locked behind requirements for costly, bias-prone annotations or access to clinical information. In collaboration with NHS Greater Glasgow and Clyde, The West of Scotland Research and Innovation Hub and the University of Glasgow a self-supervised pathology foundation model is being developed that converts groups of pixels into words, treating each whole slide image as a document to be read and understood. This approach enables large language models to interpret the spatial and contextual "narrative" within tissue, capable of learning directly from vast unlabelled datasets. It offers a scalable and interpretable path to richer insights into disease processes. Early investigations are validating its applications in clinical triage, survival prediction, biomarker discovery, and target validation.

2:50-3:15

**AYESHA AZAM**

Consultant Histopathologist and Recipient of NIHR Senior Clinical Practitioner Research Award, University Hospitals Coventry & Warwickshire NHS Trust
Workforce Readiness for AI and Digital Pathology

- How ready are the next generation of pathologists for digital pathology and AI? Early insights from multi-regional trainee surveys.
- The importance of education: moving beyond 'using' algorithms to understanding their strengths, limitations, and failure points.
- Embedding digital and AI readiness into training curricula as a foundation for future diagnostic practice.

3:15-3:40

**FRANCESCO CIOMPI**

Associate Professor and Research Group Leader of AI for Precision Medicine, Radboud University Medical Center
Computational pathology for precision medicine: development and benchmarking of artificial intelligence for oncology and beyond

One of the promises of precision medicine is to provide robust and reproducible tools to identify the right treatment for the right patient at the right time. In digital pathology, artificial intelligence (AI) has achieved human- and even super-human level performance at some diagnostic tasks and can provide the building blocks for development and discovery of novel histologic biomarkers. In this talk, I will introduce the field of computational pathology for precision medicine, show recent results on development of computational biomarkers in oncology, and sketch current and possible future directions in development and benchmarking of AI in oncology and beyond, in the era of multimodal foundation models.

3:15-3:40

**BRANKO PERUNOVIC**

Chief Medical Officer, Black Country Pathology Service, (BCPS), Royal Wolverhampton NHS Trust

**KATHERINE GLAZEBROOK**

Senior ICT Programme Manager, Black Country Pathology Service

From bricks to clicks: the pitfalls edition

Digital pathology technology works: scanners scan, AI tools analyse, dashboards display. The real challenges lie elsewhere. This talk traces the arc from early optimism to sobering reality. Press releases glow while funding lags. IT integrations appear seamless in presentations yet fray at workflow edges. Procurement freezes innovation just as enthusiasm peaks. Lateral distractions vacancy controls, shifting directives, competing agendas scatter focus. Stretched staff are asked to maintain two systems simultaneously. Meanwhile, network upgrades advance independently, colliding with digital rollouts in institutional chaos. Competing priorities jostle unpredictably, creating turbulence that leaders must navigate while maintaining momentum. These scenarios aren't complaints but executive lessons patterns recurring across healthcare systems, often unrecognised until too late. They remain invisible because organisations prefer promoting success stories over acknowledging implementation realities. The aim isn't dwelling on failure but sharpening leadership instincts. By recognising these traps early, executives can steer around them and preserve digital pathology's transformative promise amid systemic turbulence. This session examines real-world implementation challenges, offering practical strategies for maintaining project momentum when institutional forces threaten to derail digital transformation initiatives. Success requires more than good technology it demands understanding the human and organisational dynamics that determine whether innovation thrives or merely survives.

2:50-3:15

**MIEKE VERSLEGERS**

Principal Scientist Pathobiology, Preclinical Sciences and Translational Safety, Johnson & Johnson Innovative Medicine
Application of AI-driven image analysis in drug discovery and safety

In recent years, great advancements have been made to capture complex biological processes or disease states whilst still retaining spatial information on a tissue section. In the field of drug development and safety, a tight collaboration between pathologists and molecular pathology scientists is key to fully understand disease mechanisms, toxicity and safety risks based on histology, immunohistochemistry and in situ hybridization techniques. Using these assays, we present downstream analysis methods employing deep learning algorithms to decipher underlying biological mechanisms in toxicology studies and to deepen our understanding of target engagement and drug biodistribution.

3:15-3:40

**CHRISTOS MATSOUKAS**

Associate Director, Artificial Intelligence, AstraZeneca, Sweden

Stage-aware testicular histopathology evaluation with AI

- Problem: Manual staging of spermatogenesis in cross-sectioned seminiferous tubules is labor-intensive and variable, delaying testis histopathology and reducing reproducibility.
- Barrier: AI development constrained by extensive pathologist time for tubule-level segmentation and exhaustive review.
- Solution: Self-supervised and zero-shot via foundation models in rat testis studies minimize annotation burden and focus expert input, enabling a practical, consistent AI assistant for spermatogenic staging.

3:40-4:05

**SHAMILA JABBAR**

Lead Biomedical Scientist, National Pathology Imaging Co-operative (NPIC)

**ALYN CRATCHLEY**

NPIC Clinical Lead / Consultant Pathologist, National Pathology Imaging Co-operative (NPIC)

Laboratory perspective on Digital Pathology: impacts of AI in the laboratory, challenges and successes

Digital pathology (DP) is revolutionising histopathology by enabling faster, more accurate, and collaborative diagnostics that enhance patient care and laboratory efficiency. It is redefining how laboratories operate and collaborate. From experiences derived from the National Pathology Imaging Cooperative (NPIC) this presentation explores the laboratory perspective on implementing DP and AI. Biomedical scientists have been central to this transformation, embedding digital workflows, ensuring diagnostic quality, and driving innovation. We discuss key challenges in system integration, training, and change management, alongside successes in efficiency, collaboration, and AI-assisted tools. Lessons from NPIC highlight how laboratory teams can lead sustainable, AI-enabled digital transformation in pathology.

4:05

End of Conference

MAKING A POSTER PRESENTATION – CLOSING DATE 21ST NOVEMBER 2025

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters.

We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional).

Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration)

SUBMISSION INSTRUCTIONS

We will require the form [Here](#) to be submitted by the 21st November. This is the formal deadline however space is another limiting factor so early application is recommended. Therefore please contact us with any questions you have as soon as possible.

POSTER COMPETITION

- Three 15-minute speaking slots have been reserved on the Agenda for you to give an oral presentation of your research.
- Simply indicate that you would like your poster presentation to be submitted to the judging panel on the poster submission form.
- The winning entries will be notified one week after the closing date above.
- The competition is not open to representatives of organisations offering services and/or business & technology solutions or business consultants.



SUSTAINABILITY

Venues with Sustainability Goals

We are committed to selecting venues with more sustainable practices. These will cover energy supply, food & waste, water use, recycling and plastics.

Catering

You will have some great food choices while you are with us. We have worked with the caterer to increase the proportion of plant-based items. We have also built a plan with the venue to avoid waste through how they serve meals and how any leftovers are processed. Our aim is that you have some great meals, whilst with us, but with less environmental impact by the time you leave.

Travel

An international meeting does involve travel but where it is practical, please consider more sustainable alternatives to flying. The app will also have a discussion space to arrange ride shares.





DON'T DELAY, BOOK YOUR PLACE TODAY!

PHONE BOOKING

+44 (0) 1865 671957 ext. 207

maria@globalengage.co.uk

Our conference team will make all the necessary arrangements.

ONLINE BOOKING

Visit the website to book your place

www.global-engage.com/event/digital-pathology/#register

THE CONGRESS PACKAGE INCLUDES:

- All Conference Sessions
- Lunches and Refreshments
- Access to Exhibition Room
- Networking Drinks Reception
- Conference App
- E-Document Pack
- Preconference workshop – hosted by Indica Labs

FREE NEWSLETTER

For updates on the Digital Pathology & AI Congress plus free articles and reports, as and when our speakers authorise their release, sign up for updates on the event website

www.global-engage.com/event/digital-pathology

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact Gavin Hambrook at

gavin@globalengage.co.uk or call **+44 (0) 1865 849841**

T: +44 (0) 1865 849841
E: info@globalengage.co.uk
www.global-engage.com

